Encephalitis Vaccines Market Size, Share & Trends Analysis Report By Vaccine Type (Mouse brain-derived inactivated vaccine, Cell culture-derived inactivated vaccine, Cell culture-derived live attenuated vaccine), By Indication (Japanese encephalitis, Tick-borne encephalitis, Rabies encephalitis), By Age Group (Children, Adult) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Market Overview

The global encephalitis vaccines market size was valued at USD 1,344.98 Million in 2023. It is estimated to reach USD 2,164.72 Million by 2032, growing at a CAGR of 5.40% during the forecast period (2024–2032).

Vaccines against encephalitis act as biological barriers against viruses that cause inflammation in the brain. This vaccine's worldwide market includes every stage of development, manufacture, distribution, and sales. increased public knowledge of encephalitis, the existence of children vaccination programs in many countries, and the increased appeal of traveling to areas where these viruses are common are all contributing instances to the success of this market.

Several factors play a role in shaping the encephalitis vaccines market. These factors encompass the increasing incidence of encephalitis on a global scale, especially as a result of mosquito-borne viruses such as Japanese Encephalitis. Moreover, governments are actively endorsing vaccination campaigns, and there is an escalating emphasis on preventive healthcare measures aimed at safeguarding at-risk demographics.

Market Dynamics

Global encephalitis vaccines market drivers

Growing incidence of japanese encephalitis

The rising incidence of Japanese encephalitis (JE), a leading cause of viral encephalitis, is a significant driver for the encephalitis vaccines market. This trend underscores the importance of vaccination in preventing this potentially devastating disease. For instance, the report "A Bibliometric Analysis of Global Research on Japanese Encephalitis From 1934 to 2020," which was released in January 2022, states that 24 countries in Southeast Asia and the Western Pacific are home to the majority of cases of JE. The population's health and the healthcare system are heavily burdened by the about 68,000 clinical cases that are recorded annually and the over 3 billion individuals who are at risk of infection.

Increasing government initiatives

Government programs targeting at-risk areas could completely change the encephalitis vaccines market. By offering free or deeply discounted vaccines, these initiatives directly target vaccine affordability, a huge barrier in developing countries. Public education campaigns can help combat vaccine resistance and educate communities about the dangers of encephalitis. Mobile clinics deployed to remote areas further enhance accessibility, ensuring geographically dispersed populations are not left behind. In addition to significantly increasing immunization rates, this multimodal strategy has an increasing impact. The market's long-term expansion is reinforced by private healthcare providers' incentives to invest in infrastructure for vaccination delivery and storage as demand increases.

Global encephalitis vaccines market restraint

Vaccine hesitancy

One of the biggest obstacles in the vaccine encephalitis market is adverse vaccination due to misinformation and mistrust. Stakeholders must invest in successful public education efforts to overcome this barrier. These efforts must use credible sources, such as medical experts and local governments, to provide concise evidence-based information about vaccine safety and effectiveness. In addition, restoring trust and promoting acceptance of vaccination can be achieved by addressing specific issues with specific messages and encouraging public debate. By successfully combating misinformation, markets can reach their full potential and provide greater protection against this serious disease.

Global encephalitis vaccines market opportunities

Rising encephalitis burden creates urgent need for vaccination

The vaccine encephalitis market will grow as the incidence is increasing at an alarming rate worldwide. This supplement emphasizes the value of immunization as evidenced by WHO data and research. Demand for these life-saving vaccinations is expected to increase as more people seek preventative measures. For instance, as of April 28, 2022, the World Health Organization reported that 37 human cases of Japanese encephalitis had been reported in four Australian states, consisting of 25 laboratory-confirmed cases and 12 suspected cases. Furthermore, according to the research paper "Global magnitude of encephalitis burden and its evolving pattern over the past 30 years" that was released in June 2022, the global encephalitis burden in 2019 was 1,444,720 incident cases, 89,900 deaths, and 4.80 million DALYs.

New vaccine development

The market for vaccine-induced encephalitis may change due to recent and significant advances in vaccine technology. Viral vectors, DNA vaccines and recombinant components are all very promising platforms. These cutting-edge technologies have the potential to revolutionize vaccination and provide access to immunization in resource-limited settings using substitute materials or more efficient production methods. These technologies can also improve the effectiveness of immunization by targeting other virus strains or by strengthening the immune system. In addition, these platforms can improve vaccination rates, adherence and public health outcomes with multivalent vaccines that provide complete protection against multiple encephalitis viruses in a single dose.

Regional Analysis

Based on region, the global market is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

Asia pacific dominates the global market

Asia Pacific is the most significant global market shareholder and is expected to expand substantially during the forecast period. The Asia-Pacific region has the potential to become the dominant market for encephalitis vaccines owing to factors such as a growing middle class, more public awareness, government initiatives, and a high disease burden.

The China encephalitis market. The extensive population of the country is responsible for the increased demand for these products. Additionally, the substantial healthcare expenditure in the United States enables larger investments in state-of-the-art technologies. Moreover, the existence of well-known medical device companies in the nation strengthens their capacity to shape market trends.

The India encephalitis market. India has a large JE disease burden.  India is a big participant in the market for encephalitis vaccines because of its vast population, active investments in disease control initiatives, and healthcare infrastructure.

These factors are estimated to drive the Asia Pacific encephalitis market growth.

Europe region is a pivotal market for the encephalitis industry. Tick-borne encephalitis (TBE), a disease spread by infected ticks, is the main target market for encephalitis vaccines in Europe. Climate change and increasing outdoor activities are contributing to an increase in TBE incidence in Eastern Europe, a region where the disease has historically been common. The demand for TBE vaccines in the area may increase as a result of this trend and rising public awareness, which would fuel market expansion.

Czech Republic encephalitis market. Tick-borne encephalitis (TBE) has continued to be reported in high numbers in recent years, suggesting the need for immunization in that region. Both climate change and increased outdoor activities are likely to affect this growth.

Poland encephalitis market. Poland has a high rate of tick-borne encephalitis and is reporting an increase in cases. This indicates that the tick-borne encephalitis vaccines market is expanding to address this public health problem.

Thus, the factors above are estimated to boost the Europe encephalitis market growth.

Segmental Analysis

The global market is bifurcated into vaccine type, indication, and age group.

Based on vaccine type, the market is segmented into mouse brain-derived inactivated vaccine, cell culture-derived inactivated vaccine, and cell culture-derived live attenuated vaccine.

Cell culture-derived inactivated vaccine dominates the vaccine type segment. Inactivated vaccines manufactured via cell culture are anticipated to dominate the Encephalitis Vaccines industry. These vaccines offer enhanced safety, purity, and a more effective production process when compared to previous options derived from mouse brains.

Based on indication type, the market is segmented into Japanese encephalitis, tick-borne encephalitis, and rabies encephalitis.

Japanese encephalitis dominates the indication segment. Compared to tick-borne encephalitis (TBE) and rabies encephalitis, the Japanese encephalitis (JE) sector has a greater geographic prevalence, which accounts for its market dominance in encephalitis vaccinations.

Based on age group, the market is segmented into children and adult.

Children dominates the age group segment. The children segment dominates the encephalitis vaccines market due to increased sensitivity in younger age groups and routine childhood vaccinations.

Recent Developments

• In August 2021, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved TICOVAC (tick-borne encephalitis (TBE) vaccine) for active immunization to prevent TBE in individuals 1 year of age and older. TICOVAC is the only FDA-approved vaccine to help protect U.S. adults and children against the TBE virus when visiting or living in TBE endemic areas.

Analyst’s Perspective

According to analysts, the vaccine encephalitis market is growing significantly due to several factors, including increasing global disease burden, government vaccination campaigns and technological advancements in vaccines. Asia Pacific is predicted to dominate the market, especially countries with high rates of Japanese encephalitis and rising healthcare costs. But there is also potential in areas such as Eastern Europe, where tick-borne encephalitis is on the rise and travel-related vaccines are required in Europe. Overall, the market offers stimulating potential for producers to respond to the changing demands of different geographies and diseases.